

Placement completed successfully raising \$1.25 million

- Received \$1.25 million in firm commitments at 2 cents per share which will be undertaken as a 2-Tranche placement with strong support from existing institutional and sophisticated investors;
- Completed Tranche 1, raising \$835,000 (41,750,000 shares) under the Company's Placement Capacity;
- Tranche 2, totalling approximately \$415,000 (20,750,000 shares) will be completed at 2 cents per share, subject to shareholder approval at an upcoming EGM;
- HeraMED intends undertaking a rights issue to be offered to all existing shareholders, to raise a further \$1.25 million at 2 cents per share (62,500,000 shares), with documentation to be sent to shareholders in due course; and
- Proceeds to support commercial deployments, pilots, integration of HeraCARE into large health systems, private clinics and several large digital health platforms in Australia and USA.

HeraMED Limited (ASX:HMD) ('HeraMED' or the 'Company'), a medical data and technology company leading the digital transformation of maternity care, today announced that it had received \$1.25 million in firm commitments at 2 cents per share, via a 2-Tranche private placement (**Placement**).

Tranche 1 of the Placement was completed under the Company's ASX LR 7.1 Placement capacity raising approx. \$835,000 at 2 cents per share (41,750,000 shares). Tranche 2 will complete on the same terms, subject to shareholder approval to be sought at an upcoming EGM. The Placement was completed with professional and sophisticated investors within section 708(8) or section 708 (11) of the Corporations Act (Cth).

HeraMED also intends undertaking a rights issue to all shareholders to raise a further \$1.25m at the same 2 cents per share issue price (62,500,000 shares), with documentation and timetable to be sent to shareholders after completion of the Placement.

HeraMED Executive Chairman, Ron Weinberger, said: "I would like to sincerely thank both those investors that have participated in this capital raising, as well as all the shareholders that have supported our journey to date.

"The funds will be used to capitalise on the range of opportunities that exist across Australia and USA, targeted to generate commercial success.

"When I took on the role of Executive Chairman in July, my focus was to structure the business so that we could have company-wide alignment in order to develop a customer-centric and commercially focussed business. I am encouraged by the progress we have made; with an excellent team that is the nucleus of our growth now in place, that is making pleasing progress on executing our developing strategy. I am now looking to scale, and to bring more opportunities and strategic partnerships to the table.

"Our primary focus has been on building for success and shortening the sales cycle and I am confident that we will deliver on our plans in the near term," he said.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited

Executive Chairman

Dr Ron Weinberger

M: +61 406 384 189

E: ron@hera-med.com

Company Secretary

Jonathan Hart

E: Jonathan@hera-med.com

Investor Relations

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.